Abstract
Beginning in late 2015, health technology assessment (HTA) has taken the lead as the essential tool for governing how new pharmaceuticals are introduced and used in Bulgaria. Since 2017, the National Health Insurance Fund (NHIF) has reimbursed for all oncology medications included on the positive drug list (PDL) following a positive HTA recommendation. The purpose of this study is to describe the evolution of total annual cancer treatments expenditures from 2017 to 2021 following the introduction of HTA as a tool for healthcare decision-making.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
